4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
3SBio Inc. (1530) operates in the Biotechnology industry and is headquartered in Shenyang, China with about 6,109 employees. Its market capitalization is roughly CNY 44 billion. In the fiscal year ended 2025-12-31, 1530 reported CNY 17.7B in revenue and CNY 8.5B in net income.
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 17.7B | CNY 9.1B | CNY 7.8B | CNY 6.9B | — |
| Gross Profit | CNY 16.3B | CNY 7.8B | CNY 6.6B | CNY 5.7B | — |
| Operating Income (EBIT) | CNY 10.6B | CNY 2.7B | CNY 2.5B | CNY 2.1B | — |
| Net Income | CNY 8.5B | CNY 2.1B | CNY 1.5B | CNY 1.9B | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | (CNY 560M) | (CNY 555M) | (CNY 225M) | (CNY 417M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 36.3B | CNY 24.2B | CNY 23.6B | CNY 22.0B | — |
| Total Liabilities | CNY 5.8B | CNY 6.2B | CNY 7.1B | CNY 6.6B | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1530 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms